|1.||Gold, Ralf: 20 articles (12/2015 - 10/2008)|
|2.||Fox, Robert J: 13 articles (12/2015 - 09/2012)|
|3.||Dawson, Katherine T: 13 articles (03/2015 - 10/2008)|
|4.||Phillips, J Theodore: 11 articles (12/2015 - 09/2012)|
|5.||Havrdova, Eva: 11 articles (12/2015 - 10/2008)|
|6.||Kappos, Ludwig: 10 articles (12/2015 - 10/2008)|
|7.||Viglietta, Vissia: 10 articles (12/2015 - 09/2012)|
|8.||Giovannoni, Gavin: 10 articles (11/2015 - 09/2012)|
|9.||Mrowietz, Ulrich: 9 articles (01/2014 - 01/2005)|
|10.||Yang, Minhua: 8 articles (11/2015 - 10/2008)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
08/01/2013 - "Dimethyl fumarate (DMF) has been used as fungicide, but oral DMF activates anti-inflammatory and anti-oxidative pathways that are beneficial in the treatment of psoriasis. "
01/01/2007 - "Dimethyl fumarate (DMF) is used successfully to treat psoriasis. "
11/01/2014 - "This is the first field study analysing the use of Fumaderm and the improvement of quality of life in patients with psoriasis under daily outpatient conditions. "
11/01/2014 - "In this prospective, multicentre, noninterventional trial we included adult patients with severe plaque psoriasis under outpatient conditions receiving Fumaderm according to the current summary of product characteristics for systemic treatment of psoriasis. "
11/01/2014 - "This observational study recorded data on quality of life, treatment efficacy and drug dosing in patients suffering from psoriasis treated with Fumaderm under conditions of daily practice in 78 dermatological centres. "
02/01/2015 - "Obtain a more precise estimate of the efficacy of delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) in relapsing multiple sclerosis (MS) and examine the consistency of DMF's effects across patient subgroups stratified by baseline demographic and disease characteristics. "
08/10/2012 - "Dimethyl fumarate (DMF) is an effective novel treatment for multiple sclerosis in clinical trials. "
06/01/2014 - "Recent studies also report the efficacy of one FAE component, dimethylfumarate, in relapsing forms of multiple sclerosis (MS). "
10/01/2015 - "Our results offer an alternative mechanism for the efficacy of dimethyl fumarate in multiple sclerosis. "
11/01/2015 - "Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies."
|3.||Relapsing-Remitting Multiple Sclerosis
02/01/2014 - "Oral BG-12 (dimethyl fumarate), approved for the treatment of the relapsing forms of MS, has demonstrated clinical efficacy with an acceptable safety profile in the Phase III "Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting Multiple Sclerosis (RRMS)" (DEFINE) and "Comparator and an Oral Fumarate in RRMS" (CONFIRM) studies. "
11/01/2013 - "Dimethyl fumarate is an orally available treatment option for relapsing-remitting multiple sclerosis (MS) in a new formulation with improved gastroenteric coating. "
04/01/2015 - "Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF), demonstrated efficacy and safety in relapsing-remitting multiple sclerosis in the 2-year, randomized, placebo-controlled, phase 3 DEFINE and CONFIRM trials. "
02/01/2015 - "Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials."
09/01/2013 - "Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study."
10/01/2015 - "Previous reports have shown that dimethylfumarate (DMF) can activate the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2-antioxidant-responsive element (Keap1-Nrf2-ARE) system in vivo and in vitro, which leads to the downregulation of oxidative stress and inflammation. "
03/01/2011 - "In a phase II multiple sclerosis trial, BG00012 demonstrated beneficial effects on relapse rate and magnetic resonance imaging markers indicative of inflammation as well as axonal destruction. "
10/01/2015 - "Dimethyl fumarate ameliorated inflammation, reduced blood-brain barrier permeability, and improved neurological outcomes by casein kinase 2 and Nrf2 signaling pathways after experimental ICH in mice."
01/01/2015 - "In view of the limited therapeutic options for human acute and chronic polyneuritis, we used the animal model of experimental autoimmune neuritis in the Lewis rat to study the effects of dimethyl fumarate on autoimmune inflammation and neuroprotection in the peripheral nervous system. "
01/01/2010 - "Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation."
|5.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
03/01/2014 - "Intravenous immunoglobulins (IVIG) have demonstrated short- and long-term beneficial effects in CIDP but are not effective in MS. Dimethyl fumarate (BG-12), teriflunomide and laquinimod are orally administered immunomodulatory drugs that are already approved or likely to be approved in the near future for the basic therapy of patients with relapsing-remitting MS (RRMS) due to positive results in Phase III clinical trials. "
|5.||copolymer 1 (glatiramer acetate)
|5.||Nebulizers and Vaporizers (Inhaler)